The price-to-earnings ratio for Bristol-Myers Squibb Co (NYSE: BMY) is above average at 17.98x. The 36-month beta value for BMY is also noteworthy at 0.42. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 18 rating it as “hold,” and 1 rating it as “sell.”
The public float for BMY is 2.03B, and at present, short sellers hold a 1.48% of that float. The average trading volume of BMY on April 28, 2025 was 13.24M shares.
BMY) stock’s latest price update
The stock price of Bristol-Myers Squibb Co (NYSE: BMY) has dropped by -1.62 compared to previous close of 48.69. Despite this, the company has seen a fall of -2.70% in its stock price over the last five trading days. fool.com reported 2025-04-26 that It’s always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.
BMY’s Market Performance
BMY’s stock has fallen by -2.70% in the past week, with a monthly drop of -19.10% and a quarterly drop of -19.73%. The volatility ratio for the week is 3.52% while the volatility levels for the last 30 days are 4.05% for Bristol-Myers Squibb Co The simple moving average for the last 20 days is -9.64% for BMY’s stock, with a simple moving average of -11.07% for the last 200 days.
Analysts’ Opinion of BMY
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see BMY reach a price target of $55. The rating they have provided for BMY stocks is “Neutral” according to the report published on April 22nd, 2025.
Jefferies gave a rating of “Buy” to BMY, setting the target price at $70 in the report published on December 16th of the previous year.
BMY Trading at -15.28% from the 50-Day Moving Average
After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.36% of loss for the given period.
Volatility was left at 4.05%, however, over the last 30 days, the volatility rate increased by 3.52%, as shares sank -18.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.69% lower at present.
During the last 5 trading sessions, BMY fell by -2.70%, which changed the moving average for the period of 200-days by +17.23% in comparison to the 20-day moving average, which settled at $53.01. In addition, Bristol-Myers Squibb Co saw -15.31% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMY starting from BOERNER CHRISTOPHER S., who purchase 2,000 shares at the price of $55.05 back on Feb 20 ’25. After this action, BOERNER CHRISTOPHER S. now owns 104,626 shares of Bristol-Myers Squibb Co, valued at $110,096 using the latest closing price.
Hirawat Samit, the EVP,Chief Med.Offr.,Drug Dev. of Bristol-Myers Squibb Co, purchase 1,823 shares at $54.84 during a trade that took place back on Feb 14 ’25, which means that Hirawat Samit is holding 63,932 shares at $100,000 based on the most recent closing price.
Stock Fundamentals for BMY
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.72 for the gross margin
The net margin for Bristol-Myers Squibb Co stands at 0.11. The total capital return value is set at 0.18. Equity return is now at value 31.99, with 5.66 for asset returns.
Based on Bristol-Myers Squibb Co (BMY), the company’s capital structure generated 0.74 points at debt to capital in total, while cash flow to debt ratio is standing at 0.29. The debt to equity ratio resting at 2.86. The interest coverage ratio of the stock is 8.3.
Currently, EBITDA for the company is 3.17 billion with net debt to EBITDA at 3.32. When we switch over and look at the enterprise to sales, we see a ratio of 2.86. The receivables turnover for the company is 4.41for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.28.
Conclusion
In summary, Bristol-Myers Squibb Co (BMY) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
